Abstract
Abstract
Background
An alpha-fetoprotein (AFP)-positive neuroendocrine tumor of the thymus is a rare thoracic malignancy. Few cases of AFP-positive thymic large cell neuroendocrine carcinoma have been reported, with no known previous report of an AFP-positive thymic small cell carcinoma. We encountered a patient with an AFP-positive small cell carcinoma and report here the clinical course.
Case presentation
A 40-year-old man was transferred to our hospital for a large anterior mediastinal tumor and showed an elevated serum AFP level. Computed tomography-guided biopsy results led to diagnosis of small cell carcinoma. Induction chemoradiotherapy was performed before surgery because of pulmonary artery invasion. The response to Induction chemoradiotherapy varied among sites, with the main tumor showing shrinkage and the metastasis site growth. This discrepancy suggested a histologic type unresponsive to or cancer cells potentially resistant to chemotherapy, thus a surgical re-biopsy was performed and histological findings revealed AFP-positive small cell carcinoma. Additional chemotherapy was performed, though could not control cancer progression, and the patient died 8 months after the first medical examination.
Conclusions
Our present clinical experience indicates the importance of histological examination for determining AFP-positive anterior mediastinal tumor treatment. Although AFP-positive neuroendocrine tumor of the thymus is relatively rarer than germ cell carcinoma, differential diagnosis with use of a histological examination should be considered because of the potentially poorer prognosis. The present clinical findings for an AFP-positive neuroendocrine tumor of the thymus case are considered useful for establishing an optimal treatment strategy in the future.
Publisher
Springer Science and Business Media LLC
Subject
Industrial and Manufacturing Engineering,General Business, Management and Accounting,Materials Science (miscellaneous),Business and International Management
Reference10 articles.
1. Strobel P, Marx A, Chan JK, et al. Thymic neuroendocrine tumors. In: Travis WD, Brambilla E, Burke AP, et al., editors. WHO classification of tumors of the lung, pleura, thymus and heart. 4th ed. Lyon: International agency for research on cancer press; 2015. p. 234–41.
2. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann of Surg. 2010;251:1117–21.
3. Bohnenberger H, Dinter H, Konig A, Strobel P. Neuroendcrine tumors of the thymus and mediastinum. J Thorac Dis. 2017;9:1448–57.
4. Takezawa K, Okamoto I, Fukuoka J, Tanaka K, Kaneda H, Uejima H, et al. Large cell neuroendocrine carcinoma of the mediastinum with α-fetoprotein production. J Thorac Oncol. 2008;3:187–9.
5. Komisarof J, Qiu H, Velez MJ, Mulford D. Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: a case report and review. Mol Clin Oncol. 2021;14:34.